Market Signal Briefing

December 08, 2025 8:47 PM EST | Source: SOL Global Investments Corp.
Toronto, Ontario--(Newsfile Corp. - December 8, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL" or the "Company") announces that a majority vote by its Board of Directors has resolved to complete a share consolidation (the "Consolidation") of its issued and outstanding common shares (each, a "Pre-Consolidation Common Share") on the basis of ten (10) Pre-Consolidation Common Shares for one (1) post-consolidation common share (each, a "Post-Consolidation Common Share"). The Company currently has 229,997,433 Pre-Consolidation Common Shares issued and outstanding. Following the completion of the Consolidation, it is anticipated the Company will have outstanding approximately 22,999,743 Post-Consolidation Common Shares.

The record date for the Consolidation has been set as January 14, 2026, with trading of the Post-Consolidation Common Shares expected to begin on or about January 14, 2026, subject to receipt of approval from the Canadian Securities Exchange (the "CSE"). The Company's name and trading symbol will not be changed in conjunction with the Consolidation.

The Consolidation was approved at the annual general and special meeting of shareholders of the Company held on February 21, 2025. Improving conditions in the digital asset markets, including increased activity within the Solana ecosystem, have prompted the Company to take this initiative to support long-term shareholder value. The Company's strategic focus on Solana aligns with recent developments in the blockchain ecosystem and infrastructure upgrades, including the upcoming Alpenglow consensus protocol, which are expected to enhance Solana's scalability and transaction settlement speed, reinforcing the Company's investment strategy.
(Source: https://markets.financialcontent.com/wral/article/marketminute-2025-9-29-solana-eyes-unprecedented-scale-firedancer-proposes-lifting-block-compute-limits-post-alpenglow)

In connection with the Consolidation, all outstanding stock options, deferred share units ("DSUs") and performance share units ("PSUs") of the Company will be proportionately adjusted or reduced in accordance with their terms and the applicable plan documents so that their economic value is not increased or decreased as a result of the Consolidation.

Letters of transmittal will be mailed to all registered shareholders of the Company who hold their Pre-Consolidation Common Shares via physical share certificate with instructions on how to exchange existing share certificates for new share certificates.

Following the Consolidation, the Post-Consolidation Common Shares will have a new CUSIP number and a new ISIN number. No fractional shares will be issued as a result of the Consolidation. Any fractional shares resulting from the Consolidation will be rounded down to the next whole Post-Consolidation Common Share, and no cash consideration will be paid in respect of fractional shares.

About SOL Global Investments Corp.

SOL Global is one of the first publicly traded companies globally exclusively focused on digital assets. SOL Global aims to provide unprecedented public exposure to select ecosystems through token acquisitions, staking for yield generation, and investments in early-stage protocols.

Disclaimer for Forward-Looking Information

This news release contains certain information that may be deemed "forward-looking information" within the meaning of applicable securities laws. All statements herein, other than statements of historical fact, constitute forward-looking information. Such forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking information. Forward-looking information includes statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur.

Forward-looking information contained in this press release may include, without limitation, the receipt of all applicable required approvals in respect of the Consolidation, including but not limited to the approval of the CSE; the successful completion of the Consolidation on the proposed terms as described herein or at all; the intended effects of the Consolidation; the commencement of trading of the Post-Consolidation Common Shares on the CSE; the Company's aim to provide unprecedented public exposure to select ecosystems through token acquisitions, staking for yield generation, and investments in early-stage protocols; improving conditions in the digital asset markets, including increased activity within the Solana ecosystem; the upcoming Alpenglow consensus protocol, and the enhancement of Solana's scalability and transaction settlement speed; and the Company's business aims, objectives and investment strategies. Although the Company believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by its nature, forward-looking information involves assumptions and known and unknown risks, uncertainties and other factors which may cause actual results, level of activity, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with general economic conditions; adverse industry events; future legislative and regulatory developments in the digital asset sector; the Company's ability execute on its business and investment plans, including the Company's ability to raise debt or equity through future financing activities, and source and complete investments in early-stage ventures being built on the blockchain; the growth of the blockchain ecosystem; growth and development of decentralized finance and the digital asset sector; rules and regulations with respect to decentralized finance and digital assets; general business, economic, competitive, political and social uncertainties; as well as other assumptions, risks and uncertainties applicable to digital assets and to SOL Global, including as set forth in the Company's public disclosure documents filed on the SEDAR+ website at www.sedarplus.ca.

The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While the Company may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277393

December 08, 2025 7:19 PM EST | Source: Rapid Dose Therapeutics Corp.
Burlington, Ontario--(Newsfile Corp. - December 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that it has extended the maturity date of its outstanding secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing") which closed in 2023. The Notes had a maturity date of November 30, 2025, and the Company extended the maturity date for one year, to November 30, 2026.

The Financing was an offering of units (the "Units") at a price of $1.00 per Unit. Each Unit consisted of $1.00 principal amount of Notes convertible at $0.17 per share and five common share purchase warrants of the Company with an exercise price of between $0.14 and $0.17 per share and an expiry date of November 30, 2025. The Company closed all four tranches of the Financing between July 2023 and December 2023, issuing an aggregate of $3,134,445 principal amount of Notes and 15,672,225 warrants.

Specifically, noteholders holding an aggregate of $3,084,445 of Notes agreed to extend the maturity date on its Notes to November 30, 2026, and extend the expiry date on their accompanying common share purchase warrants of the Company (the "Warrants") to November 30, 2026 with an exercise price of $0.16; and such noteholders accordingly received an extension fee of 5%, payable in common shares ("Common Shares") at a price of $0.16 per share (collectively, the "Extension"). A noteholder holding $50,000 of Notes did not agree to the Extension and had their principal repaid in cash.

Pursuant to the Extension, the Notes bear interest at 18% per annum (an increase from 12% per annum), calculated and compounded monthly, and added to principal and shall otherwise continue to be paid in accordance with the original terms of the Notes. That is, interest shall be payable quarterly in arrears in Common Shares at a price per share equal to the closing market price of the Common Shares on the Canadian Securities Exchange (the "CSE") on the last trading day of each calendar quarter. The conversion price of the Notes will remain at $0.17 per share. The Company will be permitted to prepay the Notes on 10 days' advance notice without notice or bonus.

In accordance with the terms of the Notes, the Company issued Common Shares in satisfaction of the accrued and unpaid interest on the Notes for all Noteholders, due on the initial maturity date of November 30, 2025. Therefore, the Company issued 1,356,758 Common Shares at the closing market price of the Common Shares on the CSE on November 28, 2025 (the last trading day of the month), being $0.16, in satisfaction of the aggregate of $62,860.65 of accrued interest owing on the Notes at such time.

All securities issued pursuant to the Extension as well as for payment of the accrued interest are subject to a hold period expiring four months and one day from the date of issue of such securities.

Certain insiders of the Company held an aggregate of $1,696,371 of Notes and 8,481,855 Warrants and participated in the Extension and received an aggregate of 530,115 Extension fee shares. Mark Upsdell, Chief Executive Officer and a director of the Company, held $500,000 of Notes and 2,500,000 Warrants; John McKimm (via his holding company, Madison Partners Corporation), a director of the Company, held $346,371 of Notes and 1,731,855 Warrants; Christine Hrudka, a director of the Company, held $50,000 of Notes and 250,000 Warrants; and Angela O'Leary, a director of the Company, held $800,000 of Notes and 4,000,000 Warrants. Therefore, the Extension is a related party transaction within the meaning of Multilateral Instrument 61-101 ("MI 61-101"). The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in Section 5.5(b) (Company is listed on the Canadian Securities Exchange) and Section 5.7(1)(a) (fair market value of the Extension insofar as it involves related parties does not exceed 25% of the Company's market capitalization) in respect of such transaction. A resolution of the board of directors of the Company was passed to approve the Extension. The Company did not file a material change report more than 21 days before the expected closing of the Extension, which it considers reasonable in the circumstances, as the participation in the transaction by a related party of the Company was not definitive until shortly prior to the closing of the Extension and the Company needed to complete the transaction expeditiously.

About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit www.rapid-dose.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "intend", "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277386

December 08, 2025 7:21 PM EST | Source: Eric Sprott
Toronto, Ontario--(Newsfile Corp. - December 8, 2025) - Eric Sprott announces that, today, Sprott Mining Inc., a corporation which is beneficially owned by him, sold 1,400,000 common shares (Shares) of Discovery Silver Corp., over the Toronto Stock Exchange at a price of approximately $7.906 per share for aggregate consideration of $11,067,980.

Prior to the disposition of Shares, Mr. Sprott beneficially owned 82,046,998 Shares representing approximately 10.2% of the outstanding Shares. As a result of the disposition of Shares, Mr. Sprott now beneficially owns 80,646,998 Shares representing approximately 9.99% of the outstanding Shares. The disposition, combined with previous issuances of Shares, resulted in a decrease in holdings of approximately 0.8% since the date of the last filing of an Early Warning Report and brings total holdings to under 10%. As a result, Mr. Sprott and Sprott Mining ceased to be insiders of Discovery Silver Corp.

The securities noted above are held for investment purposes. Mr. Sprott has a long-term view of the investment and may acquire additional securities including on the open market or through private acquisitions or sell the securities including on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.

Discovery Silver is located at 701-55 University Ave, Toronto, Ontario, M5J 2H7. A copy of the early warning report with respect to the foregoing will appear on Discovery Silver's profile on SEDAR+ at www.sedarplus.ca and may also be obtained by calling Mr. Sprott's office at (416) 945-3294 (Sprott Mining Inc., 1106-7 King Street East, Toronto, Ontario, M5C 3C5).

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277383

STAMFORD, Conn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Star Group, L.P. (the "Company" or "Star") (NYSE:SGU), a home energy distributor and services provider, today announced financial results for its fiscal 2025 full year and fourth quarter, the three months ended September 30, 2025.

Twelve Months Ended September 30, 2025 Compared to the Twelve Months Ended September 30, 2024
For the fiscal year ended September 30, 2025, Star reported a modest rise (approximately 1.0 percent) in total revenue to $1.8 billion, reflecting higher volumes sold and higher sales of installations and services, offsetting a decline in selling prices in response to lower wholesale product costs. The volume of home heating oil and propane sold during fiscal 2025 increased by 29.2 million gallons, or 11.5 percent, to 282.6 million gallons, reflecting the additional volume provided from acquisitions and colder temperatures, more than offsetting net customer attrition and other factors. Temperatures in Star’s geographic areas of operation were 8.2 percent colder than during the prior-year period but 8.3 percent warmer than normal, as reported by the National Oceanic and Atmospheric Administration.

Star’s net income increased by $38.3 million for fiscal 2025, to $73.5 million, primarily due to a $32.4 million favorable change in the fair value of derivative instruments, $24.8 million of higher Adjusted EBITDA, and a gain of $3.8 million from the sale of real estate, partially offset by a $16.1 million increase in income tax expense, $3.9 million higher depreciation and amortization expenses (D&A), and a $2.7 million increase in interest expense. D&A and net interest expense rose largely due to acquisitions.

For fiscal 2025, Adjusted EBITDA increased by $24.8 million, or 22.2 percent, to $136.4 million compared to fiscal 2024, primarily due to an $18.5 million increase in Adjusted EBITDA in the base business and a $16.9 million increase in Adjusted EBITDA from recent acquisitions, partially offset by a $10.6 million increase in expense related to the Company's weather hedge contracts. The higher Adjusted EBITDA in the base business was driven by an increase in home heating oil and propane per gallon margins, higher home heating oil and propane volume sold (due to colder weather), and an improvement in service and installation profitability. Regarding its weather hedge, as previously reported, the temperatures experienced during the hedge period ending March 31, 2025 were colder than the strike prices and, therefore, the Company recorded an expense under those weather hedge contracts of $3.1 million. This compares to the prior-year period during which, due to warmer weather, the Company recorded a credit of $7.5 million under its weather hedge contract.

“As we close out fiscal 2025, it’s time to reflect on our recent accomplishments and near-term outlook,” said Jeff Woosnam, Star Group’s President and Chief Executive Officer. “We completed a sizable acquisition earlier this year, have kept overhead expenses largely in check, and maintained disciplined margin management. We also continue to invest in complementary installation and service offerings – which posted revenue growth of nearly 10 percent over fiscal 2024. The resulting bottom line impact of these efforts, coupled with colder temperatures, fueled a year-over-year increase in Adjusted EBITDA of $24.8 million, or 22.2 percent. We are steadfast in our mission to grow and diversify the Company by continuing to make both heating oil and propane acquisitions, keeping net attrition as low as possible, and maximizing installation and service profitability over time. We look forward to taking advantage of further opportunities to improve the organization, and its performance, in fiscal 2026.”

Three Months Ended September 30, 2025 Compared to the Three Months Ended September 30, 2024
For the fiscal 2025 fourth quarter, Star reported a 3.1 percent increase in total revenue to $247.7 million compared with $240.3 million in the prior-year period, largely reflecting higher sales of installations and services. The volume of home heating oil and propane sold during the fiscal 2025 fourth quarter rose by 1.5 million gallons, or 8.1 percent, to 20.0 million gallons, as the additional volume provided from acquisitions and other factors more than offset the impact from net customer attrition.

Star’s net loss declined by $6.4 million in the quarter, to $28.7 million, largely reflecting a favorable change in the fair value of derivative instruments of $12.2 million and a gain of $3.8 million from the sale of real estate, partially offset by a $3.6 million lower income tax benefit, a $3.3 million greater Adjusted EBITDA loss, a $1.4 million increase in net interest expense and $1.2 million higher depreciation and amortization expenses (“D&A”). As previously noted, D&A and net interest expense rose largely due to acquisitions.

The Company reported a fourth quarter Adjusted EBITDA loss (a non-GAAP measure defined below) of $33.0 million, versus an Adjusted EBITDA loss of $29.7 million in fiscal 2024, due to slightly higher operating expenses and lower home heating oil and propane per-gallon margins in the base business and an Adjusted EBITDA loss from recent acquisitions – as is typical during a non-heating season.

EBITDA and Adjusted EBITDA (Non-GAAP Financial Measures)
EBITDA (Earnings from continuing operations before net interest expense, income taxes, depreciation and amortization) and Adjusted EBITDA (Earnings from continuing operations before net interest expense, income taxes, depreciation and amortization, (increase) decrease in the fair value of derivatives, other income (loss), net, multiemployer pension plan withdrawal charge, gain or loss on debt redemption, goodwill impairment, and other non-cash and non-operating charges) are non-GAAP financial measures that are used as supplemental financial measures by management and external users of the Company’s financial statements, such as investors, commercial banks and research analysts, to assess Star’s position with regard to the following:

compliance with certain financial covenants included in our debt agreements;financial performance without regard to financing methods, capital structure, income taxes or historical cost basis;operating performance and return on invested capital compared to those of other companies in the retail distribution of refined petroleum products, without regard to financing methods and capital structure;ability to generate cash sufficient to pay interest on our indebtedness and to make distributions to our partners; andthe viability of acquisitions and capital expenditure projects and the overall rates of return of alternative investment opportunities. The method of calculating Adjusted EBITDA may not be consistent with that of other companies, and EBITDA and Adjusted EBITDA both have limitations as analytical tools and so should not be viewed in isolation but in conjunction with measurements that are computed in accordance with GAAP. Some of the limitations of EBITDA and Adjusted EBITDA are as follows:

EBITDA and Adjusted EBITDA do not reflect cash used for capital expenditures;although depreciation and amortization are non-cash charges, the assets being depreciated or amortized often will have to be replaced and EBITDA and Adjusted EBITDA do not reflect the cash requirements for such replacements;EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, working capital;EBITDA and Adjusted EBITDA do not reflect the cash necessary to make payments of interest or principal on indebtedness; andEBITDA and Adjusted EBITDA do not reflect the cash required to pay taxes. REMINDER:
Members of Star's management team will host a webcast and conference call at 11:00 a.m. Eastern Time tomorrow, December 9, 2025. The webcast will be accessible on the company’s website, at www.stargrouplp.com, and the telephone number for the conference call is 888-346-3470 (or 412-317-5169 for international callers).

About Star Group, L.P.
Star Group, L.P. is a full service provider specializing in the sale of home heating products and services to residential and commercial customers to heat their homes and buildings. The Company also sells and services heating and air conditioning equipment to its home heating oil and propane customers and, to a lesser extent, provides these offerings to customers outside of its home heating oil and propane customer base. Star also sells diesel, gasoline and home heating oil on a delivery only basis. We believe Star is the nation's largest retail distributor of home heating oil based upon sales volume. Including its propane locations, Star serves customers in the more northern and eastern states within the Northeast and Mid-Atlantic U.S. regions. Additional information is available by obtaining the Company's SEC filings at www.sec.gov and by visiting Star's website at www.stargrouplp.com, where unit holders may request a hard copy of Star’s complete audited financial statements free of charge.

Forward Looking Information
This news release includes "forward-looking statements" which represent the Company’s expectations or beliefs concerning future events that involve risks and uncertainties, including the impact of geopolitical events on wholesale product cost volatility, tariff regimes, including newly imposed U.S. tariffs and any additional responsive non-U.S. tariffs or additional U.S. tariffs, the price and supply of the products that we sell, our ability to purchase sufficient quantities of product to meet our customer’s needs, rapid increases in levels of inflation, the consumption patterns of our customers, our ability to obtain satisfactory gross profit margins, the effect of weather conditions on our financial performance, our ability to obtain new customers and retain existing customers, our ability to make strategic acquisitions, the impact of litigation, natural gas conversions and electrification of heating systems, pandemic and future global health pandemics, recessionary economic conditions, future union relations and the outcome of current and future union negotiations, the impact of current and future governmental regulations, including federal, state and municipal laws restricting greenhouse gases ("GHG") emissions and federal, state and local environmental, health, and safety regulations, the ability to attract and retain employees, customer credit worthiness, counterparty credit worthiness, marketing plans, cyber-attacks, global supply chain issues, labor shortages and new technology, including alternative methods for heating and cooling residences. All statements other than statements of historical facts included in this Report including, without limitation, the statements under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein, are forward-looking statements. Without limiting the foregoing, the words “believe,” “anticipate,” “plan,” “expect,” “seek,” “estimate,” and similar expressions are intended to identify forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to, those set forth under the heading "Risk Factors" and "Business Strategy" in our Annual Report on Form 10-K (the "Form 10-K") for the fiscal year ended September 30, 2025. Important factors that could cause actual results to differ materially from the Company’s expectations ("Cautionary Statements") are disclosed in this news release and in the Company’s Form 10-K and our Quarterly Reports on Form 10-Q. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the Cautionary Statements. Unless otherwise required by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this news release.

(financials follow)

STAR GROUP, L.P. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS  September 30,(in thousands)  2025   2024 ASSETS    Current assets    Cash and cash equivalents $24,683  $117,335 Receivables, net of allowance of $7,196 and $6,434, respectively  102,119   94,981 Inventories  47,022   41,587 Fair asset value of derivative instruments  790   — Prepaid expenses and other current assets  32,667   27,566 Total current assets  207,281   281,469 Property and equipment, net  128,605   104,534 Operating lease right-of-use assets  93,264   91,141 Goodwill  293,350   275,829 Intangibles, net  124,892   98,712 Restricted cash  250   250 Captive insurance collateral  78,189   74,851 Deferred charges and other assets, net  11,500   12,825 Total assets $937,331  $939,611 LIABILITIES AND PARTNERS’ CAPITAL    Current liabilities    Accounts payable $33,667  $31,547 Revolving credit facility borrowings  —   5 Fair liability value of derivative instruments  1,398   13,971 Current maturities of long-term debt  21,000   21,000 Current portion of operating lease liabilities  19,934   19,832 Accrued expenses and other current liabilities  119,497   116,317 Unearned service contract revenue  66,927   66,424 Customer credit balances  86,810   104,700 Total current liabilities  349,233   373,796 Long-term debt  167,118   187,811 Long-term operating lease liabilities  77,206   75,916 Deferred tax liabilities, net  30,823   21,922 Other long-term liabilities  16,171   16,273 Partners’ capital    Common unitholders  314,733   282,058 General partner  (6,605)  (5,714)Accumulated other comprehensive loss, net of taxes  (11,348)  (12,451)Total partners’ capital  296,780   263,893 Total liabilities and partners’ capital $937,331  $939,611  STAR GROUP, L.P. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS  Three Months Ended September 30, Twelve Months Ended September 30,(in thousands, except per unit data)  2025   2024   2025   2024   (unaudited) (unaudited)    Sales:        Product $156,879  $155,943  $1,437,601  $1,448,792 Installations and services  90,813   84,388   346,817   317,307 Total sales  247,692   240,331   1,784,418   1,766,099 Cost and expenses:        Cost of product  112,221   113,814   912,391   980,831 Cost of installations and services  76,046   68,637   309,161   283,444 (Increase) decrease in the fair value of derivative instruments  (1,428)  10,756   (13,390)  19,018 Delivery and branch expenses  85,927   81,392   400,830   366,381 Depreciation and amortization expenses  9,340   8,117   35,352   31,494 General and administrative expenses  7,584   7,074   30,518   28,405 Finance charge income  (1,055)  (900)  (4,915)  (4,576)Operating income (loss)  (40,943)  (48,559)  114,471   61,102 Interest expense, net  (3,209)  (1,841)  (14,323)  (11,560)Amortization of debt issuance costs  (264)  (242)  (1,068)  (988)Other income, net  3,822   —   3,822   — Income (loss) before income taxes $(40,594) $(50,642) $102,902  $48,554 Income tax expense (benefit)  (11,923)  (15,556)  29,407   13,331 Net income (loss) $(28,671) $(35,086) $73,495  $35,223 General Partner’s interest in net income (loss)  (275)  (326)  677   311 Limited Partners’ interest in net income (loss) $(28,396) $(34,760) $72,818  $34,912                   Per unit data (Basic and Diluted):        Net income (loss) available to limited partners $(0.84) $(1.00) $2.12  $0.99 Dilutive impact of theoretical distribution of earnings  —   —   0.30   0.09 Basic and diluted income (loss) per Limited Partner Unit: $(0.84) $(1.00) $1.82  $0.90          Weighted average number of Limited Partner units outstanding (Basic and Diluted)  33,616   34,686   34,276   35,273  SUPPLEMENTAL INFORMATION
STAR GROUP, L.P. AND SUBSIDIARIESRECONCILIATION OF EBITDA AND ADJUSTED EBITDA
(Unaudited)

  Three Months Ended September 30,(in thousands)  2025   2024 Net loss $(28,671) $(35,086)Plus:    Income tax benefit  (11,923)  (15,556)Amortization of debt issuance costs  264   242 Interest expense, net  3,209   1,841 Depreciation and amortization  9,340   8,117 EBITDA  (27,781)  (40,442)(Increase) / decrease in the fair value of derivative instruments  (1,428)  10,756 Other income, net  (3,822)  — Adjusted EBITDA  (33,031)  (29,686)Add / (subtract)    Income tax benefit  11,923   15,556 Interest expense, net  (3,209)  (1,841)Provision for losses on accounts receivable  286   1,097 Decrease in accounts receivables  26,861   32,502 (Increase) decrease in inventories  (3,656)  1,566 Increase in customer credit balances  30,213   34,970 Change in deferred taxes  (1,845)  (1,494)Change in other operating assets and liabilities  (13,135)  (14,059)Net cash provided by operating activities $14,407  $38,611 Net cash used in investing activities $(347) $(29,984)Net cash (used in) provided by financing activities $(17,459) $63,007           Home heating oil and propane gallons sold  20,000   18,500 Other petroleum products  32,300   33,700 Total all products  52,300   52,200  SUPPLEMENTAL INFORMATION
STAR GROUP, L.P. AND SUBSIDIARIESRECONCILIATION OF EBITDA AND ADJUSTED EBITDA
(Unaudited)

  Twelve Months Ended September 30,(in thousands)  2025   2024 Net income $73,495  $35,223 Plus:    Income tax expense  29,407   13,331 Amortization of debt issuance costs  1,068   988 Interest expense, net  14,323   11,560 Depreciation and amortization  35,352   31,494 EBITDA  153,645   92,596 (Increase) / decrease in the fair value of derivative instruments  (13,390)  19,018 Other income, net  (3,822)  — Adjusted EBITDA  136,433   111,614 Add / (subtract)    Income tax expense  (29,407)  (13,331)Interest expense, net  (14,323)  (11,560)Provision for losses on accounts receivable  6,879   8,042 (Increase) decrease in receivables  (14,011)  11,271 (Increase) decrease in inventories  (3,231)  18,475 Decrease in customer credit balances  (19,128)  (15,546)Change in deferred taxes  8,527   (3,989)Change in other operating assets and liabilities  (789)  6,002 Net cash provided by operating activities $70,950  $110,978 Net cash used in investing activities $(99,854) $(61,185)Net cash (used in) provided by financing activities $(63,748) $22,351           Home heating oil and propane gallons sold  282,600   253,400 Other petroleum products  123,900   129,100 Total all products  406,500   382,500  CONTACT: Star Group, L.P.Chris WittyInvestor RelationsDarrow Associates203/328-7310646/438-9385 or [email protected]

Analyst’s Disclosure:I/we have a beneficial long position in the shares of MDV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist December 8, 2025 8:30 AM EST

Company Participants

Danielle Keatley
Raymond Stevens - CEO & Director
Blai Coll - Chief Medical Officer

Conference Call Participants

Evan Seigerman - BMO Capital Markets Equity Research
Seamus Fernandez - Guggenheim Securities, LLC, Research Division
Terence Flynn - Morgan Stanley, Research Division
Yasmeen Rahimi - Piper Sandler & Co., Research Division
Samantha Semenkow - Citigroup Inc., Research Division
David Risinger - Leerink Partners LLC, Research Division
Jiale Song - Jefferies LLC, Research Division
Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division
Hardik Parikh - JPMorgan Chase & Co, Research Division
Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division
Patrick Dolezal - LifeSci Capital, LLC, Research Division
Corinne Jenkins - Goldman Sachs Group, Inc., Research Division
Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division

Presentation

Operator

Good day, and thank you for standing by. Welcome to the Structure Therapeutics top line results from the aleniglipron Phase II Access Program. [Operator Instructions] Please be advised that today's conference is being recorded. I'd now like to hand the conference over to Danielle Keatley, Head of Investor Relations. Please go ahead.

Danielle Keatley

Thank you, and good morning. Earlier today, we issued a press release providing top line results from Structure Therapeutics access clinical program for aleniglipron, our oral small molecule GLP-1 receptor agonist. A copy of this release and the presentation to accompany the call are available on the Investor Relations section of our website. Before we get started, I would like to remind everyone that some of the statements that we make on this call and information presented in the slide deck include forward-looking statements, which you see here. These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially.

Recommended For You

The US government will allow Nvidia  to export its H200 artificial intelligence chips to China, collecting a fee for each chip, President Trump said Monday.

Shares of Nvidia, the world’s most valuable company rose 1.2% in after-hours trading after Trump made the announcement on Truth Social, having closed 3.16% higher after Semafor first reported the possibility of approval.

Trump said that he had informed President Xi Jinping of China, where Nvidia’s chips are under government scrutiny, about the move and he “responded positively,” according to Trump’s post.

The US government will allow Nvidia  to export its H200 artificial intelligence chips to China, collecting a fee for each chip, President Trump said Monday. Above, Trump and Nvidia CEO Jensen Huang last month. AP
He added: “25% will be paid to the United States of America.”

Trump said the Commerce Department was finalizing details of the arrangement and the same approach would apply to other AI chip firms such as Advanced Micro Devices and Intel.

“We will protect National Security, create American Jobs, and keep America’s lead in AI,” Trump wrote on Truth Social. “NVIDIA’s U.S. Customers are already moving forward with their incredible, highly advanced Blackwell chips, and soon, Rubin, neither of which are part of this deal.”

Allowing the shipments could signal a friendlier approach to China, after Trump and Xi brokered a truce in the two countries’ trade and tech war in Busan, South Korea in late October.

Administration officials consider the move a compromise between sending Nvidia’s latest Blackwell chips to China, which Trump has declined to allow, and sending China no US chips at all, which officials believe would bolster Huawei’s efforts to sell AI chips in China, the person familiar with the matter said.

Nvidia and the Commerce Department did not immediately respond to requests for comment.

Trump said that he had informed President Xi Jinping of China, where Nvidia’s chips are under government scrutiny, about the move and he “responded positively,” according to Trump’s post. AP
Fears of chips strengthening China’s military
China hawks in Washington are concerned that selling more advanced AI chips to China could help Beijing supercharge its military, fears that had first prompted limits on such exports by the Biden administration.

The Trump administration had been considering greenlighting the sale, sources told Reuters last month.

Earlier media reports of H200 export approvals drew sharp criticism from Senator Elizabeth Warren, a Massachusetts Democrat who supported a bipartisan effort to reserve powerful US AI chips for US firms.

“After his backroom meeting with Donald Trump and his company’s donation to the Trump ballroom, (Nvidia) CEO Jensen Huang got his wish to sell the most powerful AI chip we’ve ever sold to China,” Warren said in a statement. “This risks turbocharging China’s bid for technological and military dominance and undermining US economic and national security.”

The H200 chip, unveiled two years ago, has more high-bandwidth memory than its predecessor, the H100, allowing it to process data more quickly. REUTERS
The H200 chip, unveiled two years ago, has more high-bandwidth memory than its predecessor, the H100, allowing it to process data more quickly.

According to a report released on Sunday by the non-partisan think tank the Institute for Progress, the H200 would be almost six times as powerful as the H20, the most advanced AI semiconductor that can legally be exported to China, after the Trump administration reversed its short-lived ban on such sales this year.

Export of the chip would allow Chinese AI labs to build AI supercomputers that achieve performance similar to top US AI supercomputers, albeit at higher costs, the report also said.

Faced with Beijing’s muscular use of export controls on rare earth minerals, which are critical for producing a raft of tech goods, Trump this year threatened new restrictions on tech exports to China, but ultimately rolled them back in most cases.

December 08, 2025 7:37 PM EST | Source: Sage Potash Corp.
Vancouver, British Columbia--(Newsfile Corp. - December 8, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company") announces a non-brokered private placement of up to 35,000,000 units of the Company ("Units") at a price of $0.20 per Unit for gross proceeds of up to $7 million (the "Offering").

Each Unit will consist of one common share in the capital of the Company (a "Common Share") and one Common Share purchase warrant of the Company (a "Warrant"). All securities issued under the Offering will be subject to a hold period of four months and one day from the date of issuance under applicable securities laws.

Each Warrant will be exercisable to purchase one Common Share at a price of $0.30 for a period of 3 years from the date of closing of the Offering.

Proceeds of the Offering will be used primarily to commence the work necessary to carry out key recommendations made by internationally recognized engineering firm, RESPEC LLC, in the Company's recently filed Preliminary Economic Assessment (see November 6, 2025 news release), including drilling of a stratigraphic hole, drill core analysis and testing and engineering review. The proceeds will also be used for working capital and for general and administrative expense purposes.

The Company may pay finders' fees in cash and/or securities of the Company in connection with the Offering.

Commenting on the Company's plan to drill the stratigraphic hole, RESPEC LLC stated, "A well-placed stratigraphic drillhole provides key data to advance mine design and increase confidence in resource estimates, supporting potential resource upgrades to reserves.* The objective for this drillhole is to confirm the mineralized thickness and grade and may enable upgrading a portion of the resource from inferred to indicated and measured. Drill results and collection of additional coring data will allow the commencement of the Bankable Feasibility Study. Our current geological confidence is high based on the 2D seismic data and the nearby Johnson 1 well (which the current resource estimate is based on). The additional stratigraphic drillhole is expected to further increase our geological confidence level, enabling the resource to potentially be expanded and upgraded."

About Sage Potash

Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) is dedicated to the development of its flagship Sage Plain Potash Project, located in the Paradox Basin, Utah. With a large and high-grade resource base, the Company is advancing toward its goal of establishing a secure and sustainable domestic potash production platform in the United States. Sage Potash is committed to food security, environmental stewardship, and creating value for shareholders and stakeholders alike.

On Behalf of the Board of Directors,

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Mineral Resources

* Mineral resources do not have a demonstrated economic value, and further exploration may not result in the estimation of a mineral reserve or enable the upgrade of current resources to a measured and indicated classification.

Cautionary Note Regarding Forward-Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. The forward-looking statements herein are made as of the date of this news release only, and the Company does not assume any obligation to update or revise them to reflect new information, estimates or opinions, future events or results or otherwise, except as required by applicable law. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budgets", "scheduled", "estimates", "forecasts", "predicts", "projects", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release includes, but is not limited to, statements regarding the Offering and with respect to future events or future performance of Sage Potash. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including, but not limited to, the risk factors set out under the heading "Risk Factors and Uncertainties" in the Company's Management's Discussion & Analysis available for review under the Company's profile at www.sedarplus.ca. Such forward-looking information represents management's best judgement based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

Not for distribution to U.S. news wire services or dissemination in the United States

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277388

Prospectus Supplement and Base Shelf Prospectus are Accessible Through SEDAR+

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE DISSEMINATION, DISTRIBUTION, RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / December 8, 2025 / Nano One Materials Corp. ("Nano One" or the "Company") (TSX:NANO)(OTCQB:NNOMF), is pleased to announce that, in connection with its previously announced overnight marketed underwritten offering (the "Offering"), it has filed a prospectus supplement dated December 8, 2025 (the "Prospectus Supplement") to its short form base shelf prospectus (the "Base Shelf Prospectus") dated April 26, 2024, in each of the provinces of Canada, except Québec, to qualify the distribution of 4,650,000 units (the "Units") of the Company at a price of C$1.40 per Unit (the "Offering Price") and up to an additional 697,500 Units at the Offering Price to be issued upon exercise of an over-allotment option, the particulars of which are further described in the Prospectus Supplement. Closing of the Offering is expected to occur on or about December 10, 2025, and is subject to satisfaction of all closing conditions, including the listing requirements of the Toronto Stock Exchange.

Prospectus Supplement and Base Shelf Prospectus is Accessible through SEDAR+

Access to the Base Shelf Prospectus, Prospectus Supplement and any amendment thereto is provided, and delivery thereof will be satisfied, in accordance with the "access equals delivery" provisions of applicable securities legislation. The Prospectus Supplement and Base Shelf Prospectus is accessible on the Company's profile at SEDAR+ at www.sedarplus.ca. An electronic or paper copy of the Base Shelf Prospectus, Prospectus Supplement and any amendment to the documents may be obtained, without charge, from Canaccord Genuity Corp. at 40 Temperance Street, Suite 2100, Toronto ON, M5H 0B4, by telephone at (416) 869-9280 or by email at [email protected] by providing the contact with an email address or address, as applicable. Prospective investors should read the Base Shelf Prospectus and Prospectus Supplement in its entirety before making an investment decision.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the 1933 Act or under any U.S. state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act, and applicable U.S. state securities laws.

About Nano One
Nano One is a technology company changing how the world makes cathode active materials for lithium-ion batteries. Applications include stationary energy storage systems (ESS), portable electronics, and electric vehicles (EVs). The Company's patented One-Pot process reduces costs, is easier-to permit, lowers energy intensity, environmental footprint, and reliance on problematic supply chains. The Company is supporting the drive towards energy security, supply chain resilience, industrial competitiveness and increased performance through process innovation. Production is being piloted and demonstrated in Candiac, Quebec, drawing on the existing plant and decades of commercial lithium-iron phosphate (LFP) manufacturing experience. Strategic collaborations and partnerships with international companies like Sumitomo Metal Mining, Rio Tinto, and Worley are supporting a design-one-build-many licensing growth strategy-delivering cost-competitive, easier-to-permit, and faster-to-market battery materials production solutions worldwide. Nano One has received funding from the Government of Canada, the Government of the United States, the Government of Québec, and the Government of British Columbia. For more information, please visit www.nanoOne.ca.

Company Contact

Paul Guedes
[email protected]
(604) 420-2041

Cautionary Note Regarding Forward-Looking Information

This press release may contain statements that may be deemed to be "forward-looking statements" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information, including, but not limited to, statements regarding the anticipated terms of the Offering and the expected closing thereof. Generally, forward-looking information may be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "proposed", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. This forward-looking information reflects Nano One's current beliefs and is based on information currently available to Nano One and on assumptions we believe are reasonable. These assumptions include, but are not limited to assumptions regarding: the Offering, including, but not limited to the terms of the Offering, the use of the net proceeds of the Offering, the offering of Units in the United States or any other jurisdiction pursuant to the Offering; changes to market conditions; changes to the regulatory climate; and such other factors and risks as disclosed in the Prospectus Supplement, Base Shelf Prospectus, the Company's most recent annual information form, management's discussion and analysis and other documents filed from time to time under the Company's profile on SEDAR+ at www.sedarplus.ca. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance, or achievements of the Company or its subsidiaries to be materially different from those expressed or implied by such forward-looking information. Such risks and uncertainties may include but are not limited to prevailing capital markets conditions, general business, economic, competitive, political and social uncertainties, changes in legislation, and lack of qualified, skilled labour or loss of key individuals. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

SOURCE: Nano One Materials Corp.

APOLLO BEACH, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, combined with advanced genetic testing, today announced the signing of an agreement to hire M. Cory Zwerling as its chief financial officer and interim chief operating officer, effective January 1, 2026. Mr. Zwerling brings more than three decades of global experience in healthcare, finance, and operations across pharmaceuticals, medical imaging, biotechnology, and digital health.

“As the Company prepares for commercialization, RetinalGenix requires a financial, strategic, and operational leader who understands regulated medical devices, clinical development, reimbursement strategy, and capital-market dynamics—and who can coordinate execution across imaging hardware, AI-enabled diagnostics, genetics, and both diagnostic and therapeutic programs.” said Jerry Katzman, MD, the Company’s Chairman, President, and CEO.

“Mr. Zwerling brings a distinctive combination of big-pharma P&L leadership, public-company governance, Medtech start-up execution, and hands-on CFO experience across healthcare technology. He has led global pharmaceutical and imaging divisions (President, Bristol-Myers Squibb Medical Imaging and other roles over his 18-year tenure at Bristol-Myers), founded and operated a healthcare IT/AI sleep-diagnostics company (CEO & co-founder, Serenium Inc), served as CEO of a medical-device venture (Zosano Pharmaceuticals), advised multiple health-technology companies, and held a public-company board seat. His background aligns directly with RetinalGenix’s strategic inflection point as the Company seeks to transition from R&D into early commercial operations. His leadership in global marketing, sales, international business management, and finance makes him uniquely equipped to guide the Company through its intended commercial launch while working to ensure disciplined capital deployment and long-term shareholder value creation,” continued Dr. Katzman.

“I'm honored to join the RetinalGenix team,” said Mr. Zwerling. “The company’s breakthrough technologies have exceptional potential to advance patient care while driving meaningful growth and value creation on a global scale.”

About RetinalGenix Technologies Inc.

RetinalGenix is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer’s disease, Complex  Dementia, and Parkinson’s disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia.

Safe Harbor Statement

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding the expected contribution of Mr. Zwerling, transitioning the Company from R&D into early commercial operations and ensuring disciplined capital deployment and long-term shareholder value creation. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, Mr. Zwerling’s ability to contribute to the Company as expected, the Company’s ability to successfully complete research and further development and commercialization of its products, the timing, cost and uncertainty of obtaining regulatory approvals for the Company’s products, the Company’s ability to protect its intellectual property, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Media Contacts:
RetinalGenix Technologies Inc.
Media and Investor Relations
[email protected]
(800) 331-5446

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effectiveness even in patients without T315I mutation (11.9 vs. 3.1 months event-free survival)
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it presented four year follow-up data from its randomized controlled, registrational Phase II study of Olverembatinib in patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. Building on results released in an oral presentation at ASH 2023, these data reaffirm Olverembatinib’s differentiated long-term efficacy and safety.

The ASH Annual Meeting is one of the largest gatherings of the international hematology community, aggregating cutting-edge scientific research and the latest data on investigational therapies that represent leading scientific and clinical advances in the global hematology field. Once again, Ascentage Pharma’s innovative pipeline has garnered significant attention at this year’s conference, with results from multiple clinical and preclinical studies on three of the Company’s investigational drug candidates (Olverembatinib, Lisaftoclax, and APG-5918) selected for presentations, including an oral report.

In the four year follow-up data, Olverembatinib consistently demonstrated a clear efficacy advantage over investigator’s choice of current best available therapy (BAT) (in China) for patients with TKI-resistant/intolerant CML-CP (including those without the T315I mutation). Among all patients with CML-CP, the Olverembatinib arm demonstrated a median event-free survival (EFS) of 21.2 months, which was significantly longer than the 2.9 months observed in the BAT arm. Among patients with CML-CP without the T315I mutation, the Olverembatinib arm demonstrated an EFS of 11.9 months, which was also significantly longer than the 3.1 months observed in the BAT arm. Notably, the long-term follow-up data showed a favorable safety profile, with vascular occlusion reported by 7% of patients.

Olverembatinib is a novel drug developed by Ascentage Pharma and represents the first third-generation BCR-ABL1 inhibitor approved in China. Olverembatinib is currently being jointly commercialized in China by Ascentage Pharma and Innovent Biologics. The drug is currently approved in China for: adult patients with TKI-resistant chronic-phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP) harboring the T315I mutation; and adult patients with CML-CP resistant to and/or intolerant of first- and second-generation TKIs, with all approved indications now covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting three global registrational Phase III studies to evaluate Olverembatinib in multiple indications, including CML-CP, newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST). Ascentage Pharma has signed an exclusive option agreement to enter into an exclusive license agreement with Takeda for Olverembatinib. In the event that Takeda exercises the option, Takeda would license the global rights to develop and commercialize Olverembatinib in all territories outside of, among others, mainland China, Hong Kong, Macau, and Taiwan, China.

Professor Qian Jiang, presenter of this study from Peking University Institute of Hematology, Peking University People’s Hospital, commented, “The latest data from this registrational Phase II study reaffirm the excellent efficacy and long-term safety of Olverembatinib in patients with TKI-resistant/intolerant CML-CP, including those without the T315I mutation. Notably, the incidence rate of vascular occlusion was 7%. These findings give physicians and patients the crucial confidence needed for long-term treatment, reinforcing the drug’s established role in clinical practice.”

Yifan Zhai, M.D., Ph.D., Chief Medical Officer of Ascentage Pharma, said, “After a four year follow-up, this pivotal study continued to mature with additional encouraging data. While affirming the drug’s durable efficacy, it also demonstrated an excellent long-term safety profile, which will contribute to patients’ quality of life and enable them to benefit from long-term treatment. Fulfilling our mission of addressing unmet clinical needs in China and around the world, we will strive to accelerate our clinical programs to bring more safe and effective therapies to patients as soon as possible.”

Highlights of the data this study reported at ASH 2025 are as below:

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations
Format: Poster Presentation
Abstract#: 3788
Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II
Time: Sunday, December 7, 2025; 06:00 PM - 08:00 PM EST
First Author: Professor Qian Jiang, M.D., Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China
Presenter: Professor Qian Jiang, M.D., Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China
Highlights:
Background:
CML is an acquired malignant clonal disease of hematopoietic stem cells. The introduction of TKIs has transformed the natural history of CML, normalizing life expectancy for many patients. However, a considerable proportion of patients eventually discontinue treatment because of acquired drug resistance or intolerance. Therefore, many patients with CML resistant to or intolerant of first- and second-generation TKIs lack effective treatment options and may face a higher risk of disease progression. Olverembatinib is a potent third-generation BCR-ABL1 TKI with strong efficacy and favorable safety in patients with CML who harbor the wild-type or T315I-mutant BCR::ABL1; the latter confers resistance against imatinib and second-generation TKIs.

Introduction:

This was an open-label, randomized controlled, multicenter, pivotal registrational Phase II study (NCT04126681) designed to evaluate the efficacy and safety of olverembatinib in patients with CML-CP resistant and/or intolerant to first- and second-generation TKIs. This report features an update on results released in an oral presentation at ASH 2023. As of January 13, 2025, a total of 144 patients with CML-CP were enrolled in the study, including 105 patients without the T315I mutation.
In this study, patients were randomized in a 2:1 ratio to the olverembatinib arm or the control arm with investigators’ choices of best available treatment (BAT).
The primary endpoint was event-free survival (EFS). An event was defined as disease progression; loss of achieved complete hematologic response (CHR), major cytogenetic response, or complete cytogenetic response (CCyR); treatment failure; no achieved CHR within 3 cycles; death from any cause; or unacceptable toxicity. Efficacy Results:

The olverembatinib arm achieved a significantly longer EFS than the BAT arm: among all patients with CML-CP, the median EFS of the olverembatinib arm and the BAT arm were 21.2 months and 2.9 months (P < 0.0001), respectively. Among patients with CML-CP without the T315I mutation, the median EFS of the olverembatinib arm and the BAT arm were 11.9 months and 3.1 months (P = 0.0159), respectively.Other efficacy parameters of the olverembatinib arm were significantly better than those of the BAT arm: among all patients with CML-CP, CHR rates of the olverembatinib arm and the BAT arm were 85% and 35%; CCyR rates were 38% and 19%; and major molecular response (MMR) rates were 30% and 8%, respectively. Among patients with CML-CP without the T315I mutation treated in the olverembatinib arm or the BAT arm, CHR rates were 82% and 50%, CCyR rates 26% and 21%, and MMR rates 16% and 10%, respectively. Safety Results: Olverembatinib showed a favorable safety profile in patients with CML-CP with/without the T315I mutation, with no new safety signals. Grade ≥ 3 adverse events included hematologic toxicities. Notably, the incidence rate of vascular occlusion in the olverembatinib arm was 7%.

Conclusion: Olverembatinib demonstrated a clear therapeutic advantage over BAT in patients with CML-CP resistant and/or intolerant to first- and second-generation TKIs, including those without the T315I mutation.

* Olverembatinib, Lisaftoclax and APG-5918 are currently under investigation and have not yet been approved by the FDA in the U.S.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.

The lead asset, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.

The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia ( AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the U.S. FDA, the EMA of the EU, and China CDE.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.

These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investor Relations:
Stella Yang
Ascentage Pharma
[email protected]
+1 (301) 792-6286

Stephanie Carrington
ICR Healthcare
[email protected]
+1 (646) 277-1282

Media Relations:
Sean Leous
ICR Healthcare
[email protected]
+1 (646) 866-4012

December 08, 2025 7:45 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - December 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Western Alliance Bancorporation (NYSE: WAL) resulting from allegations that Western Alliance Bancorporation may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Western Alliance Bancorporation securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=46349 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On October 16, 2025, Western Alliance Bancorporation disclosed that it had initiated a lawsuit against a borrower, Cantor Group V LLC, alleging fraud related to collateral loans.

On this news, Western Alliance Bancorporation's stock fell 10.88% on October 16, 2025.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277385

Gold edged higher in Asian trade, as investors await the Federal Reserve's December rate decision.

December 08, 2025 7:50 PM EST | Source: Tenaz Energy Corp.
CALGARY, ALBERTA--(Newsfile Corp. - December 8, 2025) - Tenaz Energy Corp. ("Tenaz", "We", "Our", "Us" or the "Company") (TSX: TNZ) is pleased to announce increased share ownership of the directors and officers of Tenaz following the exercise of warrants and stock options.

The warrants were previously issued under the non-brokered private placement of units completed as part of the Company's recapitalization transaction in 2021, with an expiry date in October 2026. The stock options were granted in November 2021 as long-term incentive compensation designed to align the interests of officers with the long-term accretion in the value of Tenaz common shares ("shares") through strategic acquisitions and development of the Company's assets. The stock options had an expiry date in November 2026.

In aggregate, 1.7 million warrants and 1.2 million stock options were exercised by the directors and officers, resulting in the issuance of 2.9 million shares. Of these shares, 875 thousand shares were sold at a 1% discount to market in a block trade executed by National Bank Capital Markets. Proceeds of the sale will be used to fund applicable taxes and the exercise of the warrants and stock options. Tenaz intends to use the proceeds received from the exercise of the warrants and stock options for general corporate purposes.

This transaction allowed the warrants and stock options to be exercised prior to expiry in an efficient fashion and developed additional institutional ownership of Tenaz shares. The directors and officers have retained 70% of the shares from the exercised warrants and stock options, increasing their aggregate ownership of issued and outstanding shares from 11.0% to 16.3%. The directors and officers no longer hold any warrants or stock options.

The new basic number of issued and outstanding shares is 32.0 million, with an additional 3.0 million shares issuable pursuant to outstanding deferred share units, restricted share units, performance share units and warrants. The increased share ownership by directors and officers of Tenaz illustrates the continued alignment of the board of directors and management team with shareholders of the Company. As at December 8, 2025, Tenaz directors and officers own, control or direct a total of 5.2 million shares, representing 16.3% of the issued and outstanding shares (19.5% on a fully diluted basis).

About Tenaz Energy Corp.

Tenaz is an energy company focused on the acquisition and sustainable development of international oil and gas assets. Tenaz is the largest gas producer in the Dutch sector of the North Sea and develops crude oil and natural gas at Leduc-Woodbend in Alberta. Additional information regarding Tenaz is available on SEDAR+ and at www.tenazenergy.com. Tenaz's Common Shares are listed for trading on the Toronto Stock Exchange under the symbol "TNZ".

ADVISORIES

Forward-looking Information

This press release contains certain forward-looking information and statements within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "budget", "forecast", "guidance", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "potential", "intends", "strategy" and similar expressions are intended to identify forward-looking information or statements. In particular, but without limiting the foregoing, this press release contains forward-looking information and statements pertaining to the intended use of proceeds and potential shares issuable pursuant to remaining dilutive securities.

The forward-looking information and statements contained in this press release reflect several material factors and expectations and assumptions of Tenaz including, without limitation: the continued performance of Tenaz's oil and gas properties in a manner consistent with its past experiences; that Tenaz will continue to conduct its operations in a manner consistent with past operations; expectations regarding future development; the general continuance of current industry conditions; the continuance of existing (and in certain circumstances, the implementation of proposed) tax, royalty, tariff and regulatory regimes; expectations regarding future acquisition opportunities; the continued availability of oilfield services; and the continued availability of adequate debt and equity financing and cash flow from operations to fund its planned expenditures.

Tenaz believes the material factors, expectations and assumptions reflected in the forward-looking information and statements are reasonable, but no assurance can be given that these factors, expectations, and assumptions will prove to be correct.

The forward-looking information and statements included in this press release are not guarantees of future performance and should not be unduly relied upon. Such information and statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information or statements including, without limitation: changes in commodity prices; changes in the demand for or supply of Tenaz's products; unanticipated operating results or production declines; changes in tax or environmental laws, tariffs, royalty rates or other regulatory matters; changes in development plans of Tenaz or by third party operators of Tenaz's properties; increased debt levels or debt service requirements; inaccurate estimation of reserves or resources; limited, unfavorable or a lack of access to capital markets; increased costs; a lack of adequate insurance coverage; the impact of competitors; a failure to obtain necessary approvals as proposed or at all and certain other risks detailed from time to time in Tenaz's public documents.

The forward-looking information and statements contained in this press release speak only as of the date of this press release and, except as may be required pursuant to applicable laws, Tenaz does not assume any obligation to publicly update or revise them to reflect new events or circumstances.

For further information, contact: 

Tenaz Energy Corp. 

[email protected]

 
/NOT FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277365

Bitcoin Cash has quietly become one of the best-performing layer-1 networks in the crypto sector.

One of the more notable reports I read this weekend suggested that Bitcoin Cash (BCH 2.53%) is among the best-performing layer-1 networks in the entire sector this year.

Today's Change

(

-2.53

%) $

-15.10

Current Price

$

580.54

With hundreds of such layer-1 networks available, and Bitcoin Cash now occupying 11th position in terms of market capitalization in this sector overall, this token has made an impressive year-to-date move of around 35%. Any investor should rightly be happy with that return.

Since 4 p.m. on Friday, Bitcoin Cash has surged 3.1% (as of 5 p.m. on Monday), inching its way toward a new 52-week high. Let's explore whether a new high is in store for this cryptocurrency and what investors should make of this potential move.

What's driving Bitcoin Cash higher?

Source: Getty Images.

Identifying specific catalysts for certain tokens can be a challenging task. In this case, I do think there are a range of bullish factors at play that are stoking impressive investor demand for Bitcoin Cash.

First and foremost, I've seen several reputable sources discuss Bitcoin Cash's underlying tokenomics as key to its investment thesis. Investors generally don't want to own highly inflationary tokens with future unlocks ahead, either to pay out early investors or compensate developers. Because Bitcoin Cash has a fully circulated supply, meaning no new tokens will be issued, this may prevent a rally from being derailed prematurely. That's key, as it's a surprisingly rare feature in this sector.

On the demand side of the equation, there's a lot to like about the ecosystem Bitcoin Cash has brought forward, and the growth this project has seen in true peer-to-peer transactions (the key problem many early adoptions initially thought crypto was intended to solve). This is a highly utilitarian token with real-world use cases that I think provide meaningful value.

Indeed, many market participants clearly share the same sentiment about Bitcoin Cash right now, as evidenced by this token's impressive year-to-date performance.

Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

raders push ZEC upward, but on-chain flows tell a different story.

In brief
Tether took part in a €70 million funding round for Italian humanoid robotics startup Generative Bionics.
The firm plans industrial testing and a production facility ahead of deployments targeted for 2026.
The deal adds Tether to a surge of investment in humanoid robots from tech, industrial, and financial firms.
Tether has entered the humanoid robotics race.

The company said Monday it invested in Generative Bionics as part of a €70 million (US$81 million) round, joining a sector dominated by firms like Tesla and Nvidia.

Tether said its funding will help the startup complete industrial testing and build its first production facility ahead of planned deployments in 2026.

Generative Bionics describes its machines as “Physical AI” systems designed to fuse humanoid robotics with artificial intelligence.

“Tether invests in technologies that strengthen global digital and physical infrastructure and expand human potential,” Tether CEO Paolo Ardoino said in a statement. “Humanoid robotics and Physical AI represent a powerful evolution in how intelligence and capability operate in the real world.”

For Tether, the investment continues a pattern of funding hardware and infrastructure projects beyond crypto, including artificial intelligence, media, and agriculture, and brain-computer interface technology, that sit outside its core stablecoin business.

Other firms joining Tether in the Generative Bionics fundraise included the Artificial Intelligence Fund of CDP Venture Capital, which led the round, as well as AMD Ventures, Duferco, Eni Next, and RoboIT.

Launched in 2024, Generative Bionics spun out of the Italian Institute of Technology, where researchers built more than 60 humanoid prototypes over two decades.

According to the company, 70 of the Italian Institute of Technology’s engineers joined the company and are working to turn that research into commercial robots for manufacturing, logistics, healthcare, and retail environments, bringing the label “Made in Italy” to the humanoid robot market.

Generative Bionics also said it plans to debut its first complete humanoid robot at CES 2026 in Las Vegas.

“Our mission is to build a future where intelligent humanoid robots collaborate daily with people, amplifying human cognitive and physical potential,” Generative Bionics CEO and Co-Founder, Daniele Pucci, said in a statement. “Our Physical AI enables us to design and manufacture human-inspired robots that create tangible value across multiple applications.”

Betting big on robotics

Humanoid robotics drew heavy investment in 2025. In February, Figure AI raised $675 million at a valuation of $2.6 billion.

That was followed by Bedrock Robotics in July, which secured $80 million. In April, Roundhill Investments filed for a humanoid robotics ETF, reflecting growing confidence that humanoid systems could ease labor shortages and support operations in industrial settings.

Morgan Stanley has projected the market could reach $5 trillion by 2050, led by demand in logistics and manufacturing.

Generally Intelligent NewsletterA weekly AI journey narrated by Gen, a generative AI model.

TL;DR:

A Binance employee was suspended for promoting a meme coin on the official Binance Futures account.
Binance labeled the action as “abuse of position” and contacted authorities to investigate the case.
The company rewarded the five whistleblowers who disclosed the incident with a total of $100,000.

Potential disciplinary actions could be faced by a Binance employee who has already been suspended, after the exchange discovered their connection to the launch of a new meme coin which they also promoted through the official Binance Futures account on X. The @BinanceFutures account itself reported the preliminary findings after receiving reports in its internal audit department.

Investigation of Employee Misconduct Incident

On December 7, 2025, Binance’s internal audit department received a report alleging that a Binance employee had used insider information to post on official social media and improperly obtain personal gain. We immediately launched an…

— Binance Futures (@BinanceFutures) December 8, 2025

The exchange confirmed that the employee was related to a token issued on-chain and that, minutes later, the worker allegedly used the token’s text and images in a post on the company’s official account. Binance was forceful, calling the action “abuse of their position for personal gain” and a clear violation of its policies and professional code of conduct, reaffirming its “zero tolerance” policy for behavior that undermines the platform’s integrity.

The “Year of the Yellow Fruit” Token and Conflict of Interest
The meme coin in question is “Year of the Yellow Fruit,” launched on the Four.Meme platform on BNB Chain. Following the launch, the Binance Futures account posted an image that was deleted minutes later and closely resembled the token’s design and text. This act sparked controversy in the crypto community and motivated the report that revealed the internal connection.

Despite the controversy, or perhaps because of it, the token showed green numbers, reaching a market capitalization of up to $6 million and generating over $16 million in trading volume, according to DEXScreener data. This sudden pump translated into substantial gains for some traders: at least two wallets obtained over $50,000 in profits, and eight additional traders earned at least $25,000, thanks to the employee’s improper promotion.

In summary, the investigation is active. However, in addition to the suspension, Binance indicated that it has contacted the competent authorities in the employee’s jurisdiction to take action according to legal procedures, if necessary.

As a sign of its commitment to integrity, the platform announced that the five whistleblowers who submitted valid reports to the audit department will split a $100,000 reward. This incident highlights the risks of using insider information in the volatile BNB Chain meme coin market, forcing Binance to demonstrate its strict policy against internal corruption during a time of high market volatility.

Key takeaways:

Economic uncertainty, a delayed jobs report and weakness in the housing market are causing traders to retreat from Bitcoin.

Pro traders are incurring high costs to protect against Bitcoin price drops, while in China, stablecoins are being sold at a discount to exit the crypto market.

Bitcoin (BTC) faced a $2,650 pullback after failing to break above $92,250 on Monday. The move followed a reversal in the US stock market amid uncertainty over job market conditions and growing unease about stretched valuations in artificial intelligence investments. 

Traders now wait for the US Federal Reserve (Fed) monetary policy decision on Wednesday, but the odds of a quick recovery to $100,000 depend on risk perception.

Bitcoin 3-month futures annualized basis rate. Source: Laevitas.chThe Bitcoin monthly futures premium relative to spot prices (basis rate) has remained below the neutral 5% threshold for the past two weeks. The weak demand for bullish leverage mirrors Bitcoin’s 28% decline since its October all-time high. Still, worries about global economic growth have also influenced sentiment.

Official US government data on employment and inflation has been delayed due to the 43-day funding shutdown that ended in November, resulting in reduced visibility into economic conditions. As a result, the consensus around a 0.25% interest rate cut in December has not been enough to spark optimism, especially after a private job report showed 71,321 layoffs in November.

Additional pressure came from the US real estate market after Redfin data showed that 15% of home purchase agreements were cancelled in October, citing high housing costs and rising economic uncertainty. Moreover, CNBC reported that delistings rose 38% from October 2024, while the median list price in November slipped 0.4% from a year earlier.

Bitcoin underperformed the stock market, signaling risk-aversionBitcoin’s drop to $90,000 accelerated after the forceful liquidation of $92 million in bullish leveraged BTC futures. The weak macroeconomic outlook may have pressured Bitcoin traders’ sentiment, yet the S&P 500 index stood just 1.2% below its 6,920 all-time high.

Bitcoin 30-day options skew (put-call) at Deribit. Source: laevitas.chWhales and market makers are demanding a 13% premium to sell Bitcoin put options on Deribit. The inflated cost of downside protection is typical of bearish markets. Still, the rejection at $92,000 on Monday did not affect traders’ positioning, reinforcing the $90,000 support level.

Traders have also been retreating from the cryptocurrency market in China as stablecoins have traded below parity against the local currency. This risk-off signal supports a short-term bearish outlook for Bitcoin, but it does not necessarily imply that traders expect prices to fall to $85,000 or lower.

Tether (USDT/CNY) vs. US dollar/CNY. Source: OKXUnder neutral conditions, USDT should trade at a 0.2% to 1% premium versus the official USD rate to offset cross-border frictions, regulatory hurdles, and related fees. A discount relative to the official rate indicates strong demand to exit cryptocurrency markets, a pattern often seen during bearish phases.

The lack of inflows into US spot Bitcoin exchange-traded funds (ETFs) over the past couple of weeks has also weighed on demand for bullish exposure. Whether Bitcoin can reach $100,000 in the near term will depend largely on improved visibility in the US job market and real estate conditions, which may take longer to develop than a single Fed decision.

This article is for general information purposes and is not intended to be and should not be taken as legal or investment advice. The views, thoughts, and opinions expressed here are the author’s alone and do not necessarily reflect or represent the views and opinions of Cointelegraph.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision. While we strive to provide accurate and timely information, Cointelegraph does not guarantee the accuracy, completeness, or reliability of any information in this article. This article may contain forward-looking statements that are subject to risks and uncertainties. Cointelegraph will not be liable for any loss or damage arising from your reliance on this information.

Ethereum

Price Prediction

Vitalik Buterin

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Content Writer

Harvey Hunter

Content Writer

Harvey Hunter

About Author

Harvey Hunter is a Content Writer at Cryptonews.com. With a background in Computer Science, IT, and Mathematics, he seamlessly transitioned from tech geek to crypto journalist.

Has Also Written

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Last updated: 

December 8, 2025

Vitalik Buterin is pushing for a market to predict future gas costs, a problem that has long overshadowed bullish Ethereum price predictions.

He argues that multi-year low gas fees have bred complacency, with a massive shift in retail activity to cheaper Layer 2 networks like Base and Arbitrum sidelining the altcoin’s issue.

Average Ethereum gas price. Source: Etherscan.His solution: an on-chain prediction market designed to help users secure future gas prices and mitigate sudden spikes in transaction costs on the network.

We need a good trustless onchain gas futures market.

(Like, a prediction market on the BASEFEE)

I've heard people ask: "today fees are low, but what about in 2 years? You say they'll stay low because of increasing gaslimit from BAL + ePBS + later ZK-EVM, but do I believe you?"…

— vitalik.eth (@VitalikButerin) December 6, 2025
An on-chain futures curve would provide a clear signal of long-term market expectations. It would permit users to prepay for block space and lock in costs regardless of future spikes.

With a shared reference point for future network conditions, developers could buy gas insurance to cap operating costs ahead of critical events, while heavy users could also offset future fee spikes by taking the opposite market position.

This all amounts to a more favourable platform for users, facilitating the transition from web-2 to web-3 as blockchain technology needs the reliability expected at the institutional level.

Ethereum Price Predictions: Adoption Could Fuel New All-Time HighsThe potential adoption of controlled gas fees could bring to Ethereum could help fuel the breakout of a bullish 19-month head-and-shoulder pattern, now unfolding.

The Ethereum price has confirmed a local bottom after with higher highs forming after its bounce from a historical demand zone around $2,750, and with it the right shoulder.

ETH USD 1-day chart, bullish head-and-shoulders pattern. Source: TradingView.Momentum indicators show this bullishness is now being realised. The RSI is closing in on the 50 neutral line, forming several higher lows as buyers step in.

The MACD also displays a growing lead on the signal line, suggesting a sustained bullish trend.

A fully realised pattern breakout could see the neckline reclaimed around $5,500, reclaiming past all-time highs and entering new price discovery in a 90% move.

But as the bull market matures, if Ethereum finds a bigger part to play in the transition from Web2 to Web3, the move could extend 250% to $10,000.

SUBBD: A Web3 Solution to an $85 Billion IndustryWith a shift to pro-crypto regulation, the transition to Web3 has been accelerated. And with it, platforms based in real-world utility like SUBBD ($SUBBD) are gaining traction.

Positioned as an AI-powered content platform, SUBBD is redefining the $85 billion subscriber economy by giving creators true ownership and fans genuine access.

Never miss a sale again.

As a top creator, your audience is global. It's just not possible to cater to everyone – you can't be online 24/7 🫠

That's where your personal AI Assistant comes in, to handle requests and secure payments. Sleep peacefully knowing you're making money… pic.twitter.com/ju9VjLBmea

— SUBBD (@SUBBDofficial) March 26, 2025
By cutting out the middlemen, $SUBDD puts control back in the hands of those who create real value.

Creators can monetize directly, while fans gain access to exclusive content, early releases, and meaningful interactions through token-gated perks.

The concept is already gaining traction. $SUBBD has surpassed $1.3 million in presale, as investors back the shift toward a decentralized creator economy.

With SUBBD, both sides of the community win — creators earn more, and fans get closer while embracing the decentralization use cases crypto was built for.

Visit the Official SUBBD Website Here

Follow us on Google News

TL;DR:

XRP ETFs surpassed $1 billion in assets under management less than four weeks after their launch.
The Ripple CEO attributes the success to “pent-up demand” for regulated crypto products from new investors.
XRP funds dominated flows last week, registering inflows, while Bitcoin and Ether ETFs suffered outflows.

In the daily battle for the ETF segment of the cryptocurrency market, Ripple has just made history. The company’s CEO, Brad Garlinghouse, announced that XRP ETFs surpassed $1 billion in assets under management (AUM) less than four weeks after their launch.

👀<4 weeks, and XRP is now the fastest crypto Spot ETF to reach $1B in AUM (since ETH) in the US.

With over 40 crypto ETFs launched this year in the US alone, a few points are obvious to me:

1/ there’s pent up demand for regulated crypto products, and with Vanguard opening up…

— Brad Garlinghouse (@bgarlinghouse) December 8, 2025

With this achievement, XRP becomes the fastest-growing crypto spot ETF, surpassed only by Ethereum. XRP’s accomplishment occurs amid great market turbulence, with other leading assets struggling against massive sell-offs.

“Pent-Up Demand” from Regulated Investors Drives the XRP Rally
The digital market was in a fierce battle to recover, while Garlinghouse attributed the massive inflow into XRP ETFs to “pent-up demand” for regulated products. With managers like Vanguard opening access to crypto ETFs within traditional retirement and brokerage accounts, XRP is reaching a new class of investors seeking exposure without the technical complexity.

Garlinghouse stated that this new wave of “off-chain” holders prioritizes factors like longevity, stability, and community over cycles of speculation and hype.

This theory was reflected in the ETF market action during the first week of December. XRP ETFs were the leaders of the week with $230.74 million in net inflows, extending their winning streak to four consecutive weeks. In contrast, Bitcoin and Ether ETFs registered net outflows of $87.77 million and $65.59 million, respectively.

This behavior suggests that, while Bitcoin and Ether experienced a position readjustment, investors are actively rotating liquidity toward more stable regulated funds like XRP and Solana. The unprecedented success of XRP funds, which have already attracted nearly $900 million since their debut, solidifies it as a pillar in the regulated digital financial infrastructure.

// Price

Reading time: 2 min

Published: Dec 08, 2025 at 21:18
Updated: Dec 08, 2025 at 22:28

Dogecoin's price has fallen to the projected 2.0 Fibonacci extension, or the $0.131 low.

DOGE price long-term prediction: bearish

The cryptocurrency has continued to retest the 21-day SMA barrier but has failed to sustain positive momentum above the current high. Since the price drop on October 10, sellers have maintained control, driving the price down to $0.13.

However, from November 21, as Coinidol.com reported, buyers have taken over to defend the current support level at $0.13. If sellers push Dogecoin below the $0.13 support, the price could fall as low as $0.10. For a bullish trend to begin, buyers must push the price above the 21-day SMA. DOGE is currently at $0.14.

Technical indicators

Resistance Levels $0.45 and $0.50

Support Levels – $0.30 and $0.25

Dogecoin price indicator reading

The 21-day SMA and the 50-day SMA have both declined significantly to the bottom of the chart. The 21-day SMA is acting as resistance as DOGE moves lower. On the 4-hour chart, the moving average lines are horizontal, with the 21-day SMA alternating below and above the 50-day SMA, indicating a sideways trend.

What is the next direction for Dogecoin?

Dogecoin's price is moving sideways, hovering just above the $0.13 barrier. The cryptocurrency is range-bound, trading above the $0.13 support and below the $0.155 resistance. Although the price has decreased, it is now consolidating above the $0.135 support. DOGE is likely to continue moving within this narrow range due to the presence of Doji candlesticks.

Disclaimer. This analysis and forecast are the personal opinions of the author. The data provided is collected by the author and is not sponsored by any company or token developer. This is not a recommendation to buy or sell cryptocurrency and should not be viewed as an endorsement by Coinidol.com. Readers should do their research before investing in funds.

Ethereum, the world’s second-largest cryptocurrency by market capitalization, is currently facing potential market turbulence. As of early December 2025, Ethereum’s price hovers around the $2,800 mark. If it cannot maintain this threshold and fails to attract significant trading volume, experts suggest its value may plunge toward a critical support level around $2,200. This potential decline comes as investors remain cautious about the broader cryptocurrency environment.

In recent months, Ethereum has grappled with price volatility, reflecting broader market trends. A lack of robust trading volume exacerbates this situation, as traders hesitate to engage heavily without clearer market direction. The absence of substantial volume often signals indecision among investors, making the asset vulnerable to larger price swings. Ideally, a sustainable price rally is driven by increasing volume, indicating strong market interest and confidence. Without it, the price can become susceptible to downward corrections, particularly when the broader market sentiment is uncertain.

Historically, Ethereum has experienced significant fluctuations. Its transition from proof-of-work to proof-of-stake with the Ethereum 2.0 upgrade aimed to improve scalability and environmental impact. This shift was expected to bolster investor confidence. However, the anticipated bullish momentum has been tempered by global economic conditions, regulatory uncertainties, and market skepticism about cryptocurrency longevity as a whole. Traditionally, such factors have led to cautious investor behavior, impacting price stability.

Despite Ethereum’s technological advancements, persistent issues such as high transaction fees and network congestion continue to challenge its growth. The blockchain’s competition with other emerging networks that offer faster and cheaper transactions cannot be ignored. Notably, networks like Solana and Cardano have attracted attention for their efficiency, putting pressure on Ethereum to maintain its market share.

A significant factor influencing Ethereum’s current situation is the Federal Reserve’s monetary policy. The Fed’s recent interest rate hikes, aimed at curbing inflation, have indirectly affected cryptocurrency markets. Higher interest rates typically lead to a stronger dollar, making cryptocurrencies, which are priced against it, more expensive for international investors. This dynamic has contributed to the cautious market atmosphere, as higher borrowing costs constrain potential investment flows into riskier assets like cryptocurrencies.

In addition to economic pressures, regulatory actions worldwide continue to shape the crypto landscape. Various countries are intensifying their scrutiny on digital assets, citing concerns over financial stability, money laundering, and investor protection. In the United States, proposed regulations could significantly alter how digital currencies are traded and taxed, prompting uncertainty among investors. Such regulatory developments pose risks and could potentially lead to market corrections if stringent measures are implemented.

On the positive side, Ethereum’s long-term prospects remain promising due to its foundational role in the decentralized finance (DeFi) sector and non-fungible token (NFT) markets. Both DeFi and NFTs have expanded the use cases for blockchain technology, with Ethereum at the forefront. This growth signifies that, despite short-term price fluctuations, Ethereum’s underlying technology and applications continue to appeal to developers and investors alike.

Moreover, Ethereum’s strong developer community consistently works on network improvements, maintaining its technological edge. The innovation within this ecosystem has led to the development of new applications that enhance Ethereum’s utility, potentially driving future value. These innovations could play a crucial role in rekindling investor interest and increasing trading volume, which would support price stability.

However, a notable counterpoint arises from the inherent volatility of cryptocurrency markets. The speculative nature of crypto investments means that prices can be swayed by sudden market sentiment changes or unforeseen economic events. This unpredictability poses a risk for Ethereum, as external factors outside technological advancements can rapidly alter its market trajectory.

Recent trends indicate that institutional interest in Ethereum is growing, albeit cautiously. Institutional investors, including hedge funds and asset management firms, are recognizing the potential of blockchain technology and its diverse applications. Their entry into the market could provide the much-needed volume and stability, but it also depends on regulatory developments and macroeconomic conditions.

Globally, countries are adopting varying approaches to cryptocurrency regulation, impacting market dynamics. While some nations embrace digital currencies, others impose stringent restrictions or outright bans. This divergent regulatory landscape influences where and how cryptocurrencies like Ethereum can operate, affecting investor sentiment and market behavior.

As Ethereum faces these challenges, it is crucial for investors to remain informed and consider both the risks and opportunities associated with cryptocurrency investments. The potential decline to the $2,200 support level should be viewed in the context of broader market conditions and Ethereum’s long-term strengths. While short-term volatility is likely, the continued evolution of blockchain technology and its adoption across sectors provide a robust foundation for Ethereum’s future.

Investors and analysts will closely monitor how Ethereum navigates this period of uncertainty. The performance of Ethereum in the coming months could serve as a bellwether for broader cryptocurrency trends. As the market continues to mature, Ethereum’s ability to maintain its position as a leading blockchain platform will be critical in determining its price trajectory and overall market influence.

Post Views: 11

Ethereum surged off this weekend's lows, despite bearish sentiment seen in other asset classes.

The world's second-largest cryptocurrency, Ethereum (ETH +2.44%) plays an integral role in facilitating decentralized finance applications and supporting the broader DeFi ecosystem. As the base network supporting some of the most renowned and vital applications in the digital assets sector, Ethereum's lead and massive network effects in essentially pioneering the smart contract-enabled DeFi applications that many users now take for granted have created tremendous value for investors over time.

Today's Change

(

2.44

%) $

74.38

Current Price

$

3128.77

Of course, just how richly to value these network effects-that's the tricky question. There are numerous methodologies, and an even broader swath of investors who claim their "tried and true" models work better than others.

But the reality is that market sentiment and various macro forces (such as how much capital flows into this sector) can be more essential catalysts than most care to believe.

With that in mind, let's dive into Ethereum's impressive 6.5% move off its Sunday morning lows to around $3,140 per token as of 4:30 p.m. ET (which was as low as $2,945 yesterday morning), and two key drivers that appear to be recasting the near-term narrative around Ethereum right now.

What's driving Ethereum higher today?

Source: Getty Images.

Ethereum's impressive 24-hour move comes alongside some rather bearish sentiment for investors in other risk assets, with the Nasdaq closing 0.14% lower on Monday. That's what made this particular move so compelling to me.

One key catalyst that appears to be stoking considerable investor interest in Ethereum is yet another application from BlackRock for an ETF tracking Ethereum, this time focused on Staked Ethereum. The filing for what could be an ETF trading under the ticker "ETHB" intends to provide investors not only with exposure to the price of Ethereum, but also provide a slice of staking revenues from this network. (Staking revenues are generated via the protocol's proof-of-stake model, in which tokens are locked for a specific period of time to assist in facilitating transactions).

That's an intriguing proposition, and could open up the floodgates for other ETF providers to follow suit. This is one of those catalysts I will be watching closely, as I'm sure the industry will as well.

Secondly, news that Tom Lee's BitMine Immersion Technologies now owns roughly $12 billion worth of Ethereum, following last week's purchase of an additional 138,452 ETH tokens, is notable. This amounts to approximately 3% of the entire market capitalization of Ethereum. Therefore, if Tom Lee and other institutional investors continue to accumulate these tokens in a significant manner, the supply and demand fundamentals could become even more tantalizing for bulls. That's forming an increasingly important part of the bull thesis around Ethereum (and other tokens) these days.

USDT issuer joins €70M round to fund humanoid robots built on IIT’s two-decade R&D legacy, pushing into real-world industrial AI.

Key Takeaways

Tether has invested €70 million in Generative Bionics to support intelligent humanoid robot development.
The investment aims to accelerate industrial AI robotics deployment and expand Tether's presence in advanced technologies.

Tether has invested €70 million in Generative Bionics, a funding round supporting the industrial deployment of intelligent humanoid robots.

The company is the largest spinoff from the Italian Institute of Technology and integrates over 20 years of robotics R&D, including 60 humanoid prototypes and a team of 70 engineers and AI scientists.

The investment will fund the development of Physical AI systems, a dedicated production facility, and edge AI integrations across logistics, healthcare, and manufacturing. Generative Bionics’ first robot will debut at CES 2026 in Las Vegas.

Paolo Ardoino, CEO of Tether, said the company is backing technologies that expand human potential and reduce reliance on centralized systems. The deal follows Tether’s previous investments in Blackrock Neurotech and its 20,000-GPU AI compute network built with Northern Data and Rumble.

The global humanoid robotics market is expected to exceed €200 billion by 2035, with projections reaching over €5 trillion by 2050 as industries adopt AI-driven automation at scale.

Disclaimer